Experienced Hatch-Waxman Patent Litigator
As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. Aziz has been honored among the top 3% of ANDA litigators in Patexia intelligence reports and is consistently recognized by various publications, including IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. Aziz also advises clients on FDA matters and with product selection to help clients target products for acquisition or development.
Aziz has influenced patent-related legislation by advising Congress on the America Invents Act’s (AIA) impact on industries in which his clients operate, including the:
- pharmaceutical;
- medical device;
- biotechnology;
- banking;
- Internet security;
- robotics;
- software; and
- GPS technology sectors.
Leading Litigator for Complex Cases
Drawing on his in-house experience, Aziz leverages his dual legal and technical perspective to lead scientifically complex litigation in U.S. district courts, the Federal Circuit, the U.S. Court of Federal Claims, the Patent Trial and Appeal Board (PTAB), and the U.S. International Trade Commission (ITC).
Community Involvement
Aziz frequently lectures on patent, copyright, trademark, and Hatch-Waxman Act issues and has taught courses at George Mason University. He was a board member for the University of North Carolina (UNC) Department of Biology, where he served as a liaison to faculty, students and alumni. He proudly supports nonprofit organizations serving indigent persons and children with intellectual disabilities in Northern Virginia and has successfully represented Afghans seeking asylum on a pro bono basis.
Updated Oct 2024
